Trials / Completed
CompletedNCT02218294
Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
A Phase 1 Study to Evaluate the Absorption, Metabolism and Excretion of BCX4161 Following Administration of a Single, Oral Dose of [14C]-Radiolabelled BCX4161 to Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the extent that radioactive dose of BCX4161 taken by mouth ends up in the urine, feces and expired air. If there are metabolites of BCX4161 made by the body, the chemical composition of these metabolites and their profile over time in blood and urine will be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BCX4161 |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2014-08-18
- Last updated
- 2014-10-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02218294. Inclusion in this directory is not an endorsement.